IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,077,658 | -13.8% | 226,821 | -19.3% | 0.00% | -25.0% |
| Q2 2023 | $11,689,427 | -6.5% | 281,131 | -6.6% | 0.00% | -20.0% |
| Q4 2022 | $12,497,748 | -30.7% | 301,078 | -21.9% | 0.01% | -37.5% |
| Q3 2022 | $18,022,000 | +95.5% | 385,729 | +66.3% | 0.01% | +100.0% |
| Q2 2022 | $9,220,000 | -3.8% | 231,992 | -13.6% | 0.00% | -20.0% |
| Q1 2022 | $9,583,000 | +33.7% | 268,497 | +17.0% | 0.01% | +25.0% |
| Q4 2021 | $7,167,000 | -15.6% | 229,407 | -8.1% | 0.00% | 0.0% |
| Q3 2021 | $8,493,000 | -43.8% | 249,704 | -34.5% | 0.00% | -50.0% |
| Q2 2021 | $15,111,000 | +9.9% | 381,485 | +18.4% | 0.01% | -11.1% |
| Q1 2021 | $13,755,000 | -36.3% | 322,230 | -7.3% | 0.01% | -35.7% |
| Q4 2020 | $21,589,000 | +42.6% | 347,644 | +4.0% | 0.01% | +7.7% |
| Q3 2020 | $15,137,000 | -35.2% | 334,172 | -13.6% | 0.01% | -38.1% |
| Q2 2020 | $23,370,000 | +40.1% | 386,670 | +13.6% | 0.02% | +10.5% |
| Q1 2020 | $16,684,000 | +769.9% | 340,444 | +972.4% | 0.02% | +1800.0% |
| Q4 2019 | $1,918,000 | +24.6% | 31,746 | +23.6% | 0.00% | 0.0% |
| Q3 2019 | $1,539,000 | -3.5% | 25,688 | +3.5% | 0.00% | 0.0% |
| Q2 2019 | $1,595,000 | -40.7% | 24,826 | -25.1% | 0.00% | -50.0% |
| Q1 2019 | $2,689,000 | +39.5% | 33,136 | -7.1% | 0.00% | 0.0% |
| Q4 2018 | $1,928,000 | +104.7% | 35,651 | +95.2% | 0.00% | +100.0% |
| Q3 2018 | $942,000 | +19.4% | 18,265 | -3.6% | 0.00% | 0.0% |
| Q2 2018 | $789,000 | +1.3% | 18,950 | +7.3% | 0.00% | 0.0% |
| Q1 2018 | $779,000 | -2.1% | 17,662 | +11.8% | 0.00% | 0.0% |
| Q4 2017 | $796,000 | -39.2% | 15,801 | -38.8% | 0.00% | 0.0% |
| Q3 2017 | $1,309,000 | +407.4% | 25,818 | +409.1% | 0.00% | – |
| Q2 2017 | $258,000 | +6.6% | 5,071 | -15.4% | 0.00% | – |
| Q1 2017 | $242,000 | -22.7% | 5,997 | -16.0% | 0.00% | – |
| Q4 2016 | $313,000 | +63.9% | 7,142 | +36.8% | 0.00% | – |
| Q3 2016 | $191,000 | -51.5% | 5,222 | -69.1% | 0.00% | – |
| Q2 2016 | $394,000 | -42.2% | 16,893 | +0.4% | 0.00% | -100.0% |
| Q1 2016 | $682,000 | -35.7% | 16,825 | -1.7% | 0.00% | 0.0% |
| Q4 2015 | $1,060,000 | – | 17,114 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |